Cargando…
Ticagrelor-induced Diarrhea in a Patient with Acute Coronary Syndrome Requiring Percutaneous Coronary Artery Intervention
The P2Y(12) inhibitor, ticagrelor, has been shown to prevent thrombotic events and hence, improve morbidity and mortality in patients with acute coronary syndrome following coronary artery stent placement. Despite many clinical benefits, ticagrelor has been associated with several adverse effects, i...
Autores principales: | Alomari, Mohammad, Bratton, Hunter, Musmar, Ahmad, Al Momani, Laith A, Young, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414296/ https://www.ncbi.nlm.nih.gov/pubmed/30899625 http://dx.doi.org/10.7759/cureus.3874 |
Ejemplares similares
-
Prolonged Jaundice Secondary to Amiodarone Use: A Case Report and Literature Review
por: Bratton, Hunter, et al.
Publicado: (2019) -
Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019) -
Right Coronary Artery Pseudoaneurysm With Hemopericardium: A Rare Complication of Percutaneous Coronary Intervention
por: Byrnes, Sean, et al.
Publicado: (2020) -
Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma
por: Piranavan, Paramarajan, et al.
Publicado: (2018) -
Colchicine for symptomatic coronary artery disease after percutaneous coronary intervention
por: Aw, Kah Long, et al.
Publicado: (2022)